Drug Trial Radar · NCT03519386
Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%
Last checked: Nov 19, 2026Latest source record: Nov 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
590
Actual
Start
Jul 26, 2018
Primary completion
Apr 5, 2022
Study completion Apr 2, 2024
Sponsor
- Lead sponsor
- Glaukos CorporationIndustry
- Sponsor type
- Industry
- First posted
- May 9, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase III study to compare the safety and efficacy of intraocular implants containing travoprost at two different elution rates versus Timolol Maleate Ophthalmic Solution, 0.5% (timolol) in reducing elevated intraocular pressure in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).
Conditions
- Glaucoma, Open-Angle
- Ocular Hypertension
Interventions
G2-TR intraocular implant containing travoprostCombination product
Provided in Arm/Group descriptions.
Sham surgery + active-comparator eye dropsDrug
Sham surgery plus postoperative active-comparator eye drops (timolol maleate ophthalmic solution, 0.5%).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Diurnal IOP (as Measured at 8AM and 10AM) Through 3 Months PostoperativeTime frame: 3 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Vance Thompson Vision
Sioux Falls, South Dakota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.